marginal zone lymphoma

News

BMS's Breyanzi is first CAR-T for marginal zone lymphoma

Bristol Myers Squibb has taken CAR-T therapy into new territory, after getting FDA approval for Breyanzi in marginal zone lymphoma.

R&D

The long-delayed promise of the microbiome, with Sam Possemi...

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks